The Protective Effect of Adalimumab on Renal Injury in a Model of Abdominal Aorta Cross-Clamping
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, vol.25, no.2, pp.219-226, 2016 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 25 Issue: 2
- Publication Date: 2016
- Doi Number: 10.17219/acem/33250
- Journal Name: ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.219-226
- Keywords: ischemia, reperfusion injury, adalimumab, carbonic anhydrases, tumor necrosis factor alpha, CARBONIC-ANHYDRASE-II, ISCHEMIA-REPERFUSION, ISCHEMIA/REPERFUSION INJURY, RADICAL-ANION, BICARBONATE, INFLAMMATION, EXPRESSION, INTERLEUKIN-6, PRETREATMENT, INHIBITION
- Recep Tayyip Erdoğan University Affiliated: Yes
Abstract
Background. Adalimumab (ADA) is a potent inhibitor of tumor necrosis factor (TNF-alpha). ADA treatment suppresses proinflammatory cytokines, leading to a decrease or inhibition of the inflammatory process.